Links to Abstracts

Hot topic at ESMO 2017: session focuses on adjuvant chemotherapy duration in colon cancer

ESMO PRESS RELEASE LUGANO-MADRID, 10 September, 2017 – The debate on duration of adjuvant chemotherapy for colon cancer was featured in a Special Session at the ESMO 2017 Congress in Madrid. (1)

Leaders in the field of gastrointestinal cancer discussed the controversial issue of whether three months of chemotherapy is sufficient for the adjuvant treatment of colon cancer. Is the answer the same for all patients and all treatments? What should clinicians do?

The debate stems from questions about neurotoxicity with six months of oxaliplatin-based chemotherapy, which has been the standard adjuvant therapy for stage III colon cancer since 2004. Research has probed into whether three months of treatment can provide the same benefit with fewer side effects.

The session was co-chaired by Andrés Cervantes, Chair of the ESMO Educational Committee, Medical Oncology Department, INCLIVA University of Valencia, Valencia, Spain, and Alberto Sobrero, ESMO 2017 congress co-chair, Medical Oncology Unit, IRCCS San Martino, Genova, Italy.

Results from the SCOT, TOSCA, ACHIEVE and IDEA-FRANCE trials were be presented, followed by expert interpretation by a clinician and a statistician. The implications for ESMO Clinical Practice Guidelines were discussed, and members of the panel were asked to vote for three or six months of treatment in a variety of clinical scenarios.


Notes to Editors

Please make sure to use the official name of the meeting in your reports: ESMO 2017 Congress



1 The following abstracts will be presented during Special Session ‘When clinical practice demands to go beyond statistics: Adjuvant chemotherapy of colon cancer. The 3 vs 6 month story’ on Monday, 11 September 2017, 14:45 to 16:15 (CEST) in Madrid Auditorium.

LBA21_PR ‘Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy)’ will be presented by Axel Grothey.

LBA22 ‘Updated results of the SCOT study: An International Phase III Randomised (1:1) Non-inferiority Trial Comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer’ will be presented by Timothy Iveson.

LBA23 ‘FOLFOX4/XELOX in stage II–III colon cancer: efficacy and safety results of the Italian Three or Six Colon Adjuvant (TOSCA) trial’ will be presented by Roberto Labianca.

LBA24 ‘Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for Stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration’ will be presented by Takayuki Yoshino.

473O ‘Three versus six-months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: per-protocol, subgroups and long-lasting neuropathy results’ will be presented by Julien Taieb.

About the European Society for Medical Oncology (ESMO)

ESMO is the leading professional organisation for medical oncology. With 16,000 members representing oncology professionals from over 130 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.